Vical Incorporated (Nasdaq: VICL) announced today a worldwide, nonexclusive license to Bristol-Myers Squibb Company (NYSE: BMY) of Vical's patented platform DNA immunization technology and its Vaxfectin^® adjuvant for use in the production of antibodies.
Under the agreement, Bristol-Myers Squibb will use Vical's technology to generate antibodies with potential therapeutic uses in humans. Vical will also provide specified quantities of the Vaxfectin^® adjuvant to Bristol-Myers Squibb from time to time. Financial terms of the agreement were not disclosed.(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.